PTC Therapeutics (NASDAQ:PTCT) Stock Rating Cut to Hold at Wall Street Zen

Key Points

• Wall Street Zen downgraded PTC Therapeutics to “hold” from “buy,” although the broader analyst consensus remains “Moderate Buy” with an average price target of $95.64.
• PTC’s shares fell 7% to about $59.97 after the company reported a quarterly loss of $0.62 per share, missing expectations for a $0.14 profit. Revenue nevertheless rose 69.6% year over year to $357.8 million, exceeding estimates.
• Recent developments include higher analyst price targets, increased 2026 revenue guidance, and the acquisition of ST-920, a Fabry disease gene-therapy program that could support future pipeline growth.

PTC Therapeutics (NASDAQ:PTCT - Get Free Report) was downgraded by equities researchers at Wall Street Zen from a "buy" rating to a "hold" rating in a research report issued on Saturday, Wall Street Zen reports.

Several other equities research analysts also recently commented on the stock. TD Cowen boosted their target price on shares of PTC Therapeutics from $90.00 to $95.00 and gave the stock a "buy" rating in a research report on Friday. Barclays raised their price target on shares of PTC Therapeutics from $120.00 to $122.00 and gave the company an "overweight" rating in a research report on Friday, August 14th. Truist Financial began coverage on PTC Therapeutics in a research note on Friday, October 16th. They set a "hold" rating and a $62.00 price target for the company. Morgan Stanley boosted their price objective on PTC Therapeutics from $93.00 to $104.00 and gave the stock an "overweight" rating in a report on Friday, July 31st. Finally, Royal Bank Of Canada increased their price objective on PTC Therapeutics from $75.00 to $77.00 and gave the stock a "sector perform" rating in a research note on Friday. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, three have issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $95.64.

PTC Therapeutics Stock Down 7.0%

Shares of NASDAQ:PTCT opened at $59.97 on Friday. PTC Therapeutics has a twelve month low of $58.80 and a twelve month high of $90.87. The stock's 50 day moving average is $65.36 and its 200-day moving average is $70.78.

PTC Therapeutics (NASDAQ:PTCT - Get Free Report) last announced its quarterly earnings results on Thursday, October 29th. The biopharmaceutical company reported ($0.62) EPS for the quarter, missing analysts' consensus estimates of $0.14 by ($0.76). The business had revenue of $357.81 million for the quarter, compared to analyst estimates of $306.43 million. During the same period in the previous year, the business earned $0.20 EPS. The company's quarterly revenue was up 69.6% compared to the same quarter last year. Equities analysts anticipate that PTC Therapeutics will post 1.19 EPS for the current fiscal year.

Insider Transactions at PTC Therapeutics

In related news, VP Mark Boulding sold 435 shares of the business's stock in a transaction dated Tuesday, October 6th. The shares were sold at an average price of $64.16, for a total transaction of $27,909.60. Following the transaction, the vice president directly owned 105,272 shares in the company, valued at approximately $6,754,251.52. The trade was a 0.41% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Michael Schmertzler sold 2,500 shares of the stock in a transaction dated Wednesday, October 14th. The shares were sold at an average price of $59.61, for a total transaction of $149,025.00. Following the completion of the sale, the director owned 1,291,594 shares of the company's stock, valued at approximately $76,991,918.34. This trade represents a 0.19% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 77,370 shares of company stock worth $5,322,261 in the last quarter. 5.30% of the stock is currently owned by corporate insiders.

Institutional Trading of PTC Therapeutics

Hedge funds have recently bought and sold shares of the business. Mirae Asset Global Investments Co. Ltd. bought a new position in PTC Therapeutics during the third quarter valued at $276,000. Profund Advisors LLC grew its stake in shares of PTC Therapeutics by 56.2% during the 3rd quarter. Profund Advisors LLC now owns 35,877 shares of the biopharmaceutical company's stock worth $2,324,000 after acquiring an additional 12,904 shares during the period. Vise Technologies Inc. grew its stake in shares of PTC Therapeutics by 3.1% during the 3rd quarter. Vise Technologies Inc. now owns 8,826 shares of the biopharmaceutical company's stock worth $572,000 after acquiring an additional 266 shares during the period. State of Wyoming grew its stake in shares of PTC Therapeutics by 15.3% during the 3rd quarter. State of Wyoming now owns 1,962 shares of the biopharmaceutical company's stock worth $127,000 after acquiring an additional 260 shares during the period. Finally, China Universal Asset Management Co. Ltd. increased its holdings in PTC Therapeutics by 15.4% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 15,228 shares of the biopharmaceutical company's stock worth $989,000 after acquiring an additional 2,027 shares during the last quarter.

PTC Therapeutics News Summary

Here are the key news stories impacting PTC Therapeutics this week:

• Positive Sentiment: Raised 2026 outlook and strong revenue growth: PTC reported third-quarter revenue of approximately $358 million, up 69.6% year over year, including $276 million in product revenue. Management increased full-year 2026 revenue guidance to $1.29 billion-$1.32 billion and product revenue guidance to $960 million-$990 million. Sephience revenue reached $182 million, supported by U.S. growth and international expansion. PTC Therapeutics Provides Corporate Update and Reports Third Quarter 2026 Financial Results
• Positive Sentiment: Analysts raised price targets: TD Cowen lifted its target from $90 to $95 and maintained a “buy” rating. Wells Fargo raised its target from $109 to $112 and kept an “overweight” rating, signaling substantial potential upside based on the current valuation. TD Cowen recommendations Wells Fargo price target update
• Positive Sentiment: Pipeline expansion: PTC acquired ST-920, a Fabry disease gene therapy, and expects to complete its biologics license application submission in the fourth quarter, adding a potential future growth catalyst. PTC corporate update
• Neutral Sentiment: Royal Bank of Canada raised its price target from $75 to $77 but retained a “sector perform” rating, indicating improved valuation expectations without a bullish change in its recommendation. RBC recommendations
• Negative Sentiment: Quarterly loss weighed on sentiment: PTC reported a GAAP loss of $0.62 per share, versus analysts’ expected profit of $0.14. Although revenue exceeded estimates, the earnings miss and swing from a year-earlier profit create near-term concern. Some reports cite adjusted earnings of $0.61 per share, highlighting a difference in reporting methodology. PTC Therapeutics swings to Q3 loss

About PTC Therapeutics

PTC Therapeutics, Inc is a biopharmaceutical company focused on discovering, developing and commercializing medicines for rare diseases. Its research programs include small-molecule treatments, gene therapies and other approaches designed to address conditions with limited or no available treatment options.

The company's commercial portfolio has included Emflaza (deflazacort), a corticosteroid approved in the United States to treat Duchenne muscular dystrophy, and Upstaza (eladocagene exuparvovec), a gene therapy authorized in the European Union for aromatic L-amino acid decarboxylase deficiency.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.